stockRatings News & Analysis

3 articles

Market Mood

1 Bullish0 Neutral2 Bearish
Goldman Sachs Downgrades Symrise (SY1) Due to Cyclical Concerns
MarketsBearish6/8/2026

Goldman Sachs Downgrades Symrise (SY1) Due to Cyclical Concerns

Goldman Sachs has downgraded Symrise (SY1), citing cyclical concerns impacting the stock's performance. The firm's new rating reflects a shift in market perception that could influence investor confidence. While specific figures on price targets or changes in earnings forecasts were not provided, the downgrade indicates potential challenges for Symrise in the near term. Such actions from a major financial institution can significantly sway market sentiment and trading volumes for the affected stock.

Read More
Seagate Technology (STX) Analysts Favor Long-Term Growth Potential
EarningsBullish5/3/2026

Seagate Technology (STX) Analysts Favor Long-Term Growth Potential

Seagate Technology (STX) reported better-than-expected results for Q3 FY26, prompting TD Cowen analyst Krish Sankar to raise his price target from $500 to $850. The company's FY26 Q4 earnings per share estimate is $5, exceeding Street expectations by 25%. Additionally, Marvell Technology (MRVL) is positioned to benefit from a $100 billion deal between Amazon and Anthropic for AWS technologies. Analyst Srini Pajjuri reaffirmed a buy rating on Marvell, indicating optimized prospects for both firms, particularly in the AI-driven markets.

Read More
BofA Reiterates Underperform on Sarepta Therapeutics Amid Trial Data
EarningsBearish3/25/2026

BofA Reiterates Underperform on Sarepta Therapeutics Amid Trial Data

BofA has maintained an Underperform rating for Sarepta Therapeutics due to findings from early trial data. This reiteration could impact investor sentiment and trading volumes for Sarepta shares. The company's stock performance may be influenced by the evaluation of its clinical data, which could affect future funding and development. Investors will be closely watching further trial results and BofA's future assessments.

Read More